The cytotoxic effects of glycyrrhizic acid-modified chitosan/selenium nanocomposite on osteosarcoma cancer cell line
Résumé
This study focuses on the preparation, characterization, and application of glycyrrhizic acid (GA)-modified chitosan/selenium (Cs/Se) nanocomposites (NC) for treating osteosarcoma cancer cells. The Cs-stabilized Se nanoparticles (Cs/Se NPs) were synthesized through a chemical reduction method, where GA was added via a surface modification technique to enhance biocompatibility and targeting efficiency. Characterization of the GA-Cs/Se NC and Cs/Se NPs was performed using various techniques, including transmission electron microscopy (TEM), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), and Zeta potential analysis. These analyses confirmed the successful formation of spherical NPs with a uniform size (100–200 nm) and good distribution with appropriate surface modifications. GA-Cs/Se NC exhibited potent cytotoxicity against MG-63 osteosarcoma cells, with an IC50 of 76.65 ± 3.5 µg/ml, whereas it had negligible effects on bone marrow stromal cells, confirming selective tumor targeting. Additionally, gene expression analysis revealed an 8.07-fold upregulation of the pro-apoptotic Bax and a 0.36-fold downregulation of the anti-apoptotic Bcl-2, indicating mitochondrial-mediated apoptosis. Moreover, qRT-PCR revealed a 7.13-fold increase in p53 expression, corroborating the induction of DNA damage-induced apoptotic pathways. The novel GA-Cs/Se NC developed in this study uniquely integrates the ROS-mediated pro-apoptotic activity of Se NPs with the inhibitory and anti-inflammatory properties of GA, all within a Cs NPs matrix that improves stability, biocompatibility, and cellular uptake. This multifunctional design enables a synergistic mechanism combining oxidative stress induction with transcriptional modulation to selectively target and kill osteosarcoma cells while minimizing necrosis and inflammation.
Citer ce document
Accès au document
Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter
Voir l'article sur le site de la revueStatistiques
Consultations : 1
Téléchargements : 0